PROJECT NARRATIVE The work in this proposal focuses on further development of TT001 to protect from cisplatin- induced hearing loss, an anticancer drug that leaves 40-60% of the treated cancer patients with high frequency hearing loss. If successful, this proposal will allow Ting Therapeutics to initiate conversations with pharmaceutical companies for the manufacturing and commercialization of TT001, for its use as a standard otoprotective component of cisplatin-based therapies.
|Effective start/end date||12/1/21 → 11/30/22|
- National Institute on Deafness and Other Communication Disorders: $566,238.00
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.